This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, Y. Articles by Ishitsuka, H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, Y. Articles by Ishitsuka, H.

Antitumor Activity of Indomethacin in Mice Bearing Advanced Colon 26 Carcinoma Compared with Those with Early Transplants

Nippon Roche Research Center, Kajiwara 200, Kamakura City, Kanagawa 247, Japan

The antitumor activity of indomethacin (IND) was investigated in mice bearing advanced colon 26 adenocarcinoma compared with its early transplants. Treatment with 0.001% IND in drinking water retarded the growth of tumor when commenced at Day 1 after the tumor inoculation. The suppression of the tumor growth by IND continued up to 4 to 5 weeks as long as the size of the tumor remained small. On the other hand, IND given to mice bearing a large burden of the tumor at 2 weeks after the inoculation had facilitated the tumor growth. IND reduced tumor-associated PGE₂ production in mice bearing either small or large burdens of the tumors. These results indicate that the antitumor activity of IND depends on tumor size and therefore is not simply associated with the reduction of PGE₂ levels. We found that colon 26 caused changes in parameters reported for tumor cachexia, such as weight loss, wasting of muscle and adipose tissues and hypoglycemia, when it grew to around 1 g at 2–3 weeks after the tumor inoculation. IND given to the mice with large burdens of colon 26 alleviated the cachexia of the mice, resulting in the increase of the survival time even though the growth of the tumor had been facilitated. It is possible that IND affects the tumor growth and survival by reversing tumor-induced disorders in homeostasis.

Received 2/27/89. Revised 6/26/89. Accepted 8/ 7/89.

This article has been cited by other articles:

				G. Hawcroft, S. H. Gardner, and M. A. Hull Activation of Peroxisome Proliferator-Activated Receptor gamma Does Not Explain the Antiproliferative Activity of the Nonsteroidal Anti-Inflammatory Drug Indomethacin on Human Colorectal Cancer Cells J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 632 - 637. [Abstract] [Full Text] [PDF]

				S. E. Samuels, A. L. Knowles, T. Tilignac, E. Debiton, J. C. Madelmont, and D. Attaix Higher skeletal muscle protein synthesis and lower breakdown after chemotherapy in cachectic mice Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R133 - R139. [Abstract] [Full Text] [PDF]

				R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]

				H-H. S. Chow, D. L. Earnest, D. Clark, N. Mason-Liddil, C. B. Kramer, J. G. Einspahr, J. M. Guillen-Rodriguez, D. J. Roe, W. Malone, J. A. Crowell, et al. Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 351 - 356. [Abstract] [Full Text]

				S.-S. Yeh and M. W Schuster Geriatric cachexia: the role of cytokines Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197. [Abstract] [Full Text] [PDF]

				D. D. Lazarus, A. T. Destree, L. M. Mazzola, T. A. McCormack, L. R. Dick, B. Xu, J. Q. Huang, J. W. Pierce, M. A. Read, M. B. Coggins, et al. A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E332 - E341. [Abstract] [Full Text] [PDF]